Compare HALO & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HALO | GTLB |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 5.5B |
| IPO Year | 2001 | 2021 |
| Metric | HALO | GTLB |
|---|---|---|
| Price | $115.13 | $48.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 27 |
| Target Price | ★ $78.64 | $37.17 |
| AVG Volume (30 Days) | 1.7M | ★ 5.1M |
| Earning Date | 05-05-2026 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | $151,862,000.00 | ★ $955,224,000.00 |
| Revenue This Year | $28.24 | $18.72 |
| Revenue Next Year | $12.56 | $16.05 |
| P/E Ratio | $35.84 | ★ N/A |
| Revenue Growth | N/A | ★ 25.81 |
| 52 Week Low | $61.23 | $18.73 |
| 52 Week High | $113.47 | $55.55 |
| Indicator | HALO | GTLB |
|---|---|---|
| Relative Strength Index (RSI) | 66.83 | 63.60 |
| Support Level | $103.47 | $46.01 |
| Resistance Level | N/A | $55.55 |
| Average True Range (ATR) | 2.62 | 2.13 |
| MACD | -0.46 | -0.19 |
| Stochastic Oscillator | 72.84 | 38.05 |
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
GitLab Inc operates on an all-remote model. GitLab is a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation, following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, & the Asia Pacific. It focused on accelerating innovation & broadening the distribution of its platform to companies across the world.